This podcast reviews current and emerging approaches to residual disease detection in diffuse large B-cell lymphoma, emphasizing the role of PET-CT imaging in assessing treatment response and predicting relapse risk. Dr. David Russler-Germain discusses the limitations of PET-CT and highlights growing evidence that ctDNA-based MRD testing may provide more accurate prognostic information and improve post-treatment disease monitoring.